

Supplemental Table 4. Uni- and multivariate analysis OS.

Survival	All Patients (34)	Cases	Univariable Cox HR [CI]	p value <sup>1</sup>	Multivariable Cox HR [CI]	p value
<b>Age</b>						
Median, years (range)	34	30	1.03 [1.00-1.06]	0.07	1.01 [0.97-1.05]	0.55
<b>WHO performance score (%)</b>						
0	20	17	1		1	
1, 2 or missing	14	13	2.26 [1.05-4.85]	<b>0.04</b>	5.82 [2.11-16.08]	<b>0.001</b>
<b>LDH (%)</b>						
Normal	18	17	1		1	
Elevated (>250 U/L)	16	13	0.94 [0.46-1.95]	0.87	1.36 [0.62-3.00]	0.45
<b>Brain metastases (%)</b>						
No/ not confirmed	22	20	1		1	
Yes	12	10	1.03 [0.47-2.24]	0.95	2.55 [0.95-6.84]	0.06
<b>Pretreated immunotherapy</b>						
No	14	12	1		1	
Yes	20	18	2.05 [0.90-4.64]	0.09	3.65 [1.35-9.87]	<b>0.01</b>
<b>Absolute leukocyte count before IFNa (x 10<sup>9</sup>/L)</b>						
Median (range)	34	30	1.20 [1.07-1.36]	<b>0.003</b>		
<b>Absolute neutrophil count before IFNa (x 10<sup>9</sup>/L)</b>						
Median (range)	34	30	1.21 [1.07-1.37]	<b>0.003</b>		
<b>Absolute monocyte count before IFNa (x 10<sup>9</sup>/L)</b>						
Median (range)	34	30	5.87 [1.60-21.62]	<b>0.008</b>		
<b>Absolute lymphocyte count before IFNa (x 10<sup>9</sup>/L)</b>						
Median (range)	34	30	0.77 [0.14-1.43]	0.41		
<b>Leukocyte/lymphocyte ratio</b>						
Median (min-max)	34	30	1.14 [1.03-1.26]	<b>0.02</b>		
<b>Neutrophil/lymphocyte ratio</b>						
Median (min-max)	34	30	1.13 [1.02-1.26]	<b>0.03</b>		
<b>Monocyte/lymphocyte ratio</b>						
Median (min-max)	34	30	3.59 [1.83-7.05]	<b>&lt;0.0001</b>	4.12 [1.75-9.81]	<b>0.001</b>

<sup>1</sup> Statistically significant p values are indicated in bold.

In the univariate analysis clinical parameters known to be associated with survival in metastatic melanoma patients were included. From the known (possible) predictors measured in routine blood testing (complete blood count) for response to immunotherapy MLR was selected in the final multivariate model for both OS as it was the strongest predictor for survival in the univariate analysis.